First Clinical Trial of Innovative Cancer Drug Targeting HSF1 Pathway Begins
Photo: Institute of Cancer Research
The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.
The drug, called NXP800, was discovered at The Institute of Cancer Research, London, and targets the pathway regulated by the HSF1 transcription factor.
HSFI is a 'master switch' in cells that controls the activity of a variety of genes—and its signaling is hijacked by a variety of cancers to support their growth and spread.
The phase I clinical trial is sponsored by oncology-focused biopharmaceutical ...